Anti-Hypertension Effect of Vanylidilol: A Phenylaldehyde α/β-Adrenoceptor Blocker with Endothelium-Dependent and K + Channels Opening-Associated Vasorelaxant Activities

Pharmacology

Volumn 70, Issue 3, 2004, Pages 140-151

  Chiu, Chaw Chi ^a   Wu, Jiunn Ren ^a   Lee, Chih Hsiung ^a   Liou, Shwu Fen ^a   Dai, Zen Kong ^a   Chen, Ing Jun ^a   Yeh, Jwu Lai ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Adrenoceptor blockade; K+ channels; Nitric oxide; Radioligand binding assay; Vasorelaxant effect

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; ALDEHYDE DERIVATIVE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; APAMIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHARYBDOTOXIN; ENDOTHELIUM DERIVED RELAXING FACTOR; GLIBENCLAMIDE; ISOPRENALINE; METHYLENE BLUE; N(G) NITROARGININE METHYL ESTER; PENTOBARBITAL; PHENYL GROUP; PHENYLEPHRINE; POTASSIUM CHANNEL STIMULATING AGENT; PRAZOSIN; RADIOLIGAND; UNCLASSIFIED DRUG; VANYLIDILOL; VASODILATOR AGENT;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; BRAIN MEMBRANE; CHRONOTROPISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG EFFECT; DRUG STRUCTURE; GUINEA PIG; HEART LEFT ATRIUM; HEART RATE; HEART RIGHT ATRIUM; HEART VENTRICLE; HYPERTENSION; INOTROPISM; ISOLATED ARTERY; ISOLATED HEART; ISOLATED ORGAN; LUNG PARENCHYMA; MEAN ARTERIAL PRESSURE; MUSCLE TONE; NONHUMAN; PRIORITY JOURNAL; RAT; THORACIC AORTA; TRACHEA; VASOCONSTRICTION; VASODILATATION;

ADMINISTRATION, ORAL; ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ALDEHYDES; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA, THORACIC; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; GUINEA PIGS; HEART ATRIA; HEART RATE; ION CHANNEL GATING; ISOPROTERENOL; MALE; METHYLENE BLUE; MYOCARDIAL CONTRACTION; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PIPERAZINES; POTASSIUM CHANNELS; RADIOLIGAND ASSAY; RATS; RATS, INBRED SHR; RATS, WISTAR; RECEPTORS, ADRENERGIC, BETA; TRACHEA; VASODILATOR AGENTS;

EID: 0442309056     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074977     Document Type: Article

References (35)

1. Brittain RT, Drew GM, Levy GP: The alpha- and beta-adrenoceptor blocking potencies of labetalol and its individual stereoisomers in anaesthetized dogs and in isolated tissues. Br J Pharmacol 1982;77:105-114.
2. Sponer G, Bartsch W, Strein K, Muller-Beckmann B, Bohm E: Pharmacological profile of carvedilol as a β-blocking agent with vasodilating and hypotensive properties. J Cardiovasc Pharmacol 1987;9:317-327.
3. Sheu MM, Wu BN, Ho WC, Chen IJ: Vanidilol: A vanilloid-type vasorelaxant and ocular hypotensive beta-adrenoceptor blocker with partial beta-2-agonist activity. Pharmacology 1997;54:211-224.
4. 2-agonist activity. Drug Dev Res 1999;47:77-89.
5. 2-adrenoceptor agonist associated vasorelaxant activities. J Cardiovasc Pharmacol 1999;34:10-20.
6. Yeh JL, Yang TH, Liang JC, Huang YC, Lo YC, Wu JR, Lin YT, Chen IJ: Isoeugenodilol: A vasorelaxant α/β-adrenoceptor blocker with antioxidant activities. Drug Dev Res 2000;51:29-42.
7. Chiu CC, Lin YT, Tsai CH, Liang JC, Chiang LC, Wu JR, Chen IJ, Yeh JL: Pharmacological effects of an aldehyde type α/β-adrenoceptor blocking agent with vasodilating properties. Gen Pharmacol 2000;34:391-400.
8. 1-adrenoceptor antagonist with α-adrenoceptor blocking and potassium channel opening activities. Drug Dev Res 2002;55:104-117.
9. Yeh JL, Wu JR, Chiu CC, Chen YW, Lo YC, Lin YT, Cheng CJ, Chen IJ: Vanillylamide-based propanolamine derivative displays α/β- adrenoceptor blocking and vasodilating properties. J Cardiovasc Pharmacol 2002;39:803-813.
10. Michael RE: Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol 1993;71:12C-22C.
11. Manktelow C, Bigatello LM, Hess D, Hurford WE: Physiologic determinants of the response to inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesthesiology 1997;87:297-307.
12. + channel opening and stimulation of cyclic GMP in the vasorelaxant effects of nicorandil in isolated piglet pulmonary and mesenteric arteries: Relative efficacy and interactions between both pathways. Br J Pharmacol 1998;123:847-854.
13. Ignarro LJ: Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol 1990;30:535-560.
14. + channels. Trends Pharmacol Sci 1989;10:431-435.
15. ATP openers. J Cardiovasc Pharmacol 1994;24(suppl 4):S12-S17.
16. + channels in pulmonary hypertension. Vasc Pharmacol 2002;38:25-33.
17. Chen IJ, Yeh JL, Liou SJ, Shen AY: Guaiacoxypropanolamine derivatives of capsaicin: A new family of β-adrenoceptor blockers with intrinsic cardiotonic properties. J Med Chem 1994;37:938-943.
18. Chen IJ, Yeh JL, Lo YC, Sheu SH, Lin YT: Capsinolol: The first β-adrenoceptor blocker with an associated calcitonin gene-related peptide releasing activity in the heart. Br J Pharmacol 1996;119:7-14.
19. 2-agonist activity derived from ferulic acid, an active component of Ligusticum wallichii Franch. J Cardiovasc Pharmacol 1998;31:750-757.
20. 1-adrenoceptor antagonist with tracheal and vascular smooth muscle relaxant properties. Jpn J Pharmacol 1999;80:127-136.
21. Yeh JL, Liou SF, Liang JC, Huang YC, Chiang LC, Wu JR, Lin YT, Chen IJ: Vanidipinedilol: A vanilloid-based β-adrenoceptor blocker displaying calcium entry blocking and vasorelaxant activities. J Cardiovasc Pharmacol 2000;35:51-63.
22. + channels opening activities in rat aortic smooth muscle. Br J Pharmacol 2001;134:265-274.
23. + channels. Br J Pharmacol 2002;135:1159-1166.
24. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
25. Harada S, Ban T, Fujita T, Koshiro A: Negative inotropic effects and the hydrophobicity of beta-adrenergic blocking agents. Arch Int Pharmacodyn Ther 1981;252:262-271.
26. Godfraind T: EDRF and cyclic GMP control gating of receptor-operated calcium channels in vascular smooth muscle. Eur J Pharmacol 1986;126:341-343.
27. Karaki H, Weiss GB: Calcium channels in smooth muscle. Gastroenterology 1984;87:960-970.
28. + channels in cultured vascular smooth muscle. Circ Res 1993;74:471-476.
29. Brand FN, Larson MG, Kannel WB, McGuirk JM: The occurrence of Raynaud's phenomenon in a general population: The Framingham Study. Vasc Med 1997;2:296-301.
30. van Zwieten PA: Development and trends in the drug treatment of essential hypertension. J Hypertens Suppl 1992;10:S1-12.
31. Maes M, Westenberg H, Vandoolaeghe E, Demedts P, Wauters A, Neels H, Meltzer HY: Effects of trazodone and fluoxetine in the treatment of major depression: Therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine. J Clin Psychopharmacol 1997;17:358-364.
32. Betti L, Botta M, Corelli F, Floridi M, Giannaccini G, Maccari L, Manetti F, Strappaghetti G, Tafi A, Corsano S: Alpha(1)-adrenoceptor antagonists. 4. Pharmacophore-based design, synthesis, and biological evaluation of new imidazo-, benzimidazo-, and indoloarylpiperazine derivatives. J Med Chem 2002;45:3603-3611.
33. Caccia S: Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 1998;34:281-302.
34. Shapiro HK: Carbonyl-trapping therapeutic strategies. Am J Ther 1998;5:323-353.
35. 1-adrenoceptor blocking agent. Arch Int Pharmacodyn Ther 1993;321:30-40.